NEUROCRINE BIOSCIENCES INC's ticker is and the CUSIP is 64125CAD1. A total of 45 filers reported holding NEUROCRINE BIOSCIENCES INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $157,000 | +16.3% | 106,000 | 0.0% | 0.00% | – |
| Q2 2023 | $135,000 | +1587.5% | 106,000 | +1666.7% | 0.00% | – |
| Q1 2023 | $8,000 | -11.1% | 6,000 | 0.0% | 0.00% | – |
| Q4 2022 | $9,000 | 0.0% | 6,000 | -14.3% | 0.00% | – |
| Q3 2022 | $9,000 | +12.5% | 7,000 | +16.7% | 0.00% | – |
| Q2 2022 | $8,000 | 0.0% | 6,000 | 0.0% | 0.00% | – |
| Q1 2022 | $8,000 | +14.3% | 6,000 | 0.0% | 0.00% | – |
| Q4 2021 | $7,000 | -12.5% | 6,000 | 0.0% | 0.00% | – |
| Q3 2021 | $8,000 | +60.0% | 6,000 | +50.0% | 0.00% | – |
| Q2 2021 | $5,000 | 0.0% | 4,000 | 0.0% | 0.00% | – |
| Q1 2021 | $5,000 | -16.7% | 4,000 | 0.0% | 0.00% | – |
| Q4 2020 | $6,000 | 0.0% | 4,000 | 0.0% | 0.00% | – |
| Q3 2020 | $6,000 | -14.3% | 4,000 | 0.0% | 0.00% | – |
| Q2 2020 | $7,000 | +40.0% | 4,000 | 0.0% | 0.00% | – |
| Q1 2020 | $5,000 | -16.7% | 4,000 | 0.0% | 0.00% | – |
| Q4 2019 | $6,000 | – | 4,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TENOR CAPITAL MANAGEMENT Co., L.P. | 45,447,000 | $60,497,000 | 1.31% |
| SHENKMAN CAPITAL MANAGEMENT INC | 4,366,000 | $5,924,000 | 0.54% |
| Aequim Alternative Investments LP | 7,609,000 | $10,088,000 | 0.43% |
| MACKAY SHIELDS LLC | 27,806,000 | $37,405,000 | 0.35% |
| Weiss Asset Management LP | 10,000,000 | $13,290,000 | 0.33% |
| WOLVERINE ASSET MANAGEMENT LLC | 13,230,000 | $17,541,000 | 0.13% |
| Polar Asset Management Partners Inc. | 7,500,000 | $9,942,000 | 0.10% |
| LORD, ABBETT & CO. LLC | 22,141,000 | $29,732,000 | 0.07% |
| Calamos Advisors LLC | 7,500,000 | $9,967,000 | 0.05% |
| D. E. Shaw & Co., Inc. | 39,270,000 | $52,046,000 | 0.04% |